Andrew Plump, MD, PhD, is the Chief Medical and Scientific Officer (CMSO) for Takeda and is and a member of the company’s Board of Directors. In his position, he leads Takeda’s global R&D organization. Andy provides strategic direction and oversight for all Takeda research and development activities globally.
Andy brings an unwavering focus on patients and a deep commitment to innovation and positive change in the healthcare industry. To continue and accelerate Takeda’s R&D successes, he leads an organization that focuses on people and partnerships, modality diversification, translational medicine and genomics.
Prior to assuming his current role, Andy served as Senior Vice President, Research & Translational Medicine, Deputy to the President of R&D at Sanofi where he was responsible for global research and translational medicine across all therapeutic areas.
Before his global leadership role at Sanofi, Andy spent more than 10 years at Merck, where he began his industry career in one of the industry's premier Clinical Pharmacology groups. He ultimately assumed the position Vice President, Worldwide Cardiovascular (CV) Research Head.
Andy received his medical degree from the University of California, San Francisco (UCSF), his doctorate in cardiovascular genetics with Dr. Jan Breslow from the Rockefeller University, and his bachelor’s degree from the Massachusetts Institute of Technology. He completed a residency in Internal Medicine and a fellowship in Medical Genetics at UCSF. Following his clinical training, Andy continued his scientific training in neuroscience as a Howard Hughes and Stanley J. Sarnoff postdoctoral fellow, with Dr. Marc Tessier-Lavigne, concurrently assuming faculty responsibilities as an Adjunct Clinical Instructor in the Department of Medical Genetics.